COMPREHENSIVE LESION TRAJECTORY ANALYSIS
Patient with Stage IV Non-Small Cell Lung Cancer (Adenocarcinoma)
Tracking Period: January 15, 2024 - January 30, 2025 (14 months)

================================================================================
TIMELINE OF SCANS
================================================================================
RPT-001: 2024-01-15 - Baseline (pre-treatment)
RPT-002: 2024-03-18 - Post 2 cycles chemotherapy (+63 days)
RPT-003: 2024-05-22 - Post 4 cycles chemotherapy (+128 days from baseline)
RPT-004: 2024-08-28 - Maintenance therapy (+226 days from baseline)
RPT-005: 2025-01-30 - Disease progression (+381 days from baseline)

================================================================================
LESION TRAJECTORY BY SITE
================================================================================

PRIMARY TUMOR
-------------
Lesion ID: L001
Location: Right upper lobe, anterior segment
Type: Primary adenocarcinoma

Measurements (max diameter in cm):
RPT-001 (Baseline):    3.2 cm - Spiculated with pleural retraction
RPT-002 (+63 days):    2.4 cm - Decreased 25% (Partial Response)
RPT-003 (+128 days):   1.8 cm - Decreased 44% from baseline (Major PR)
RPT-004 (+226 days):   1.8 cm - Stable (Sustained response)
RPT-005 (+381 days):   2.6 cm - Increased 44% from prior (Progressive Disease)

Clinical Notes: Initial excellent response to chemotherapy with 44% reduction.
Maintained stability for 3 months on maintenance therapy, then significant
progression.

PULMONARY METASTASES
--------------------
Lesion ID: L002
Location: Left lower lobe, lateral basal segment

Measurements:
RPT-001: 0.6 cm - Solid nodule
RPT-002: 0.4 cm - Decreased 33%
RPT-003: 0.3 cm - Decreased 50% from baseline
RPT-004: 0.3 cm - Stable
RPT-005: 0.7 cm - Increased 133% from prior, now larger than baseline

---

Lesion IDs: L003, L004
Location: Multiple bilateral pulmonary nodules

Evolution:
RPT-001: Multiple small nodules (< 0.5 cm) in both lungs
RPT-002: Decreased in size and number
RPT-003: Complete resolution (no longer visualized)
RPT-004: Remained resolved
RPT-005: Multiple new nodules reappeared bilaterally

---

Lesion ID: L010 (NEW)
Location: Right middle lobe
RPT-005: 0.8 cm - New pulmonary metastasis

MEDIASTINAL LYMPH NODES
------------------------
Lesion ID: L005
Location: Right paratracheal (Station 4R)

Measurements (long axis x short axis in cm):
RPT-001: 1.8 x 1.2 cm (short axis 1.2 cm - ENLARGED)
RPT-002: 1.3 x 0.9 cm (decreased 28%)
RPT-003: 1.0 x 0.7 cm (decreased 44% from baseline)
RPT-004: 1.0 x 0.7 cm (stable)
RPT-005: 2.1 x 1.5 cm (increased 110% from prior, approaching baseline)

---

Lesion ID: L006
Location: Subcarinal (Station 7)

Measurements:
RPT-001: 1.5 x 1.0 cm (borderline enlarged)
RPT-002: 1.2 x 0.8 cm (decreased)
RPT-003: 0.9 x 0.6 cm (normalized to normal size)
RPT-004: 0.9 x 0.6 cm (stable)
RPT-005: 1.8 x 1.3 cm (increased 100%, now larger than baseline)

---

Lesion ID: L011 (NEW)
Location: Left hilum (Station 10L)
RPT-005: 1.4 x 1.0 cm - New nodal disease

ADRENAL METASTASES
------------------
Lesion ID: L007
Location: Right adrenal gland

Measurements:
RPT-001: 1.2 cm - Indeterminate nodule
RPT-002: 1.2 cm - Stable (likely metastasis)
RPT-003: 1.0 cm - Slight decrease (responding)
RPT-004: 1.0 cm - Stable (controlled)
RPT-005: 2.3 cm - Increased 130%, significantly enlarged

---

Lesion ID: L014 (NEW)
Location: Left adrenal gland
RPT-005: 1.1 cm - New adrenal metastasis

PLEURAL EFFUSIONS
-----------------
Lesion ID: L008
Location: Right pleural space

Evolution:
RPT-001: 1.5 cm depth - Small effusion
RPT-002: Resolved
RPT-003: Remained resolved
RPT-004: Remained resolved
RPT-005: 3.5 cm depth - Recurred, now moderate (worse than baseline)

---

Lesion ID: L009 (NEW)
Location: Left pleural space
RPT-005: 1.2 cm depth - New small effusion

HEPATIC METASTASES (NEW SITE)
------------------------------
Lesion ID: L012 (NEW)
Location: Liver segment VII
RPT-005: 2.1 x 1.8 cm - New liver metastasis

---

Lesion ID: L013 (NEW)
Location: Liver segment V
RPT-005: 1.3 cm - New liver metastasis

OSSEOUS METASTASES (NEW SITE)
------------------------------
Lesion ID: L015 (NEW)
Location: T8 vertebral body
RPT-005: Sclerotic lesion - New bone metastasis

RETROPERITONEAL NODES (NEW SITE)
---------------------------------
Lesion ID: L016 (NEW)
Location: Para-aortic region
RPT-005: 1.6 x 1.2 cm - New retroperitoneal adenopathy

PERITONEAL DISEASE (NEW SITE)
------------------------------
Lesion ID: L017 (NEW)
Location: Peritoneal cavity
RPT-005: Moderate ascites - New peritoneal involvement

PERICARDIAL EFFUSION (NEW)
---------------------------
Lesion ID: L018 (NEW)
Location: Pericardial space
RPT-005: Small effusion - New finding

================================================================================
RESPONSE SUMMARY BY TIMEPOINT
================================================================================

BASELINE (RPT-001): Initial staging
- Primary tumor: 3.2 cm
- Multiple bilateral pulmonary nodules
- Mediastinal lymphadenopathy
- Right adrenal nodule (indeterminate)
- Small right pleural effusion
- Provisional Stage: IV (T2bN2M1b)

POST 2 CYCLES CHEMO (RPT-002): Partial Response
- Primary tumor: 25% decrease
- Pulmonary nodules: decreased
- Lymph nodes: decreased
- Pleural effusion: resolved
- Overall: Excellent response

POST 4 CYCLES CHEMO (RPT-003): Continued Partial Response
- Primary tumor: 44% decrease from baseline
- Pulmonary nodules: near complete resolution
- Lymph nodes: continued decrease
- Overall: Major response, nearing complete response

MAINTENANCE THERAPY (RPT-004): Stable Disease
- All lesions stable
- No new lesions
- Excellent disease control maintained

PROGRESSION (RPT-005): Progressive Disease
- Primary tumor: 44% increase from prior scan
- New pulmonary nodules throughout both lungs
- Marked increase in lymph node sizes
- NEW SITES OF METASTASES:
  * Liver (2 lesions)
  * Bone (T8 vertebra)
  * Left adrenal
  * Peritoneum (ascites)
  * Pericardial effusion
- Right adrenal: 130% increase
- Bilateral pleural effusions recurred
- Overall: Significant multi-system progression

================================================================================
TREATMENT TIMELINE AND OUTCOMES
================================================================================

Phase 1: Induction Chemotherapy (Jan-May 2024)
- Regimen: Carboplatin + Pemetrexed x 4 cycles
- Outcome: Excellent partial response (44% tumor reduction)

Phase 2: Maintenance Therapy (May-Jan 2024-2025)
- Regimen: Pemetrexed monotherapy
- Duration: ~8 months of disease control
- Outcome: Initial stability, then progression

Phase 3: Progressive Disease (Jan 2025)
- Status: Multi-system progression with new distant metastases
- Next steps: Change systemic therapy, molecular profiling, palliative care

================================================================================
KEY CLINICAL MILESTONES
================================================================================

✓ Day 0: Diagnosis of Stage IV NSCLC (adenocarcinoma)
✓ Day 63: Partial response to chemotherapy (25% reduction)
✓ Day 128: Major partial response (44% reduction from baseline)
✓ Day 226: Stable disease on maintenance therapy
✗ Day 381: Progressive disease with new distant metastases

Total duration of disease control: ~11 months
Progression-free survival: ~11 months

================================================================================
LESION COUNT SUMMARY
================================================================================

                    Baseline  2-Cycles  4-Cycles  Maintenance  Progression
Primary Tumor          1         1         1          1            1
Pulmonary Mets        Multiple   Few      1-2        1-2         Multiple
Mediastinal LN         2         2         2          2            3
Liver Mets            0         0         0          0            2
Adrenal Mets          1         1         1          1            2
Bone Mets             0         0         0          0            1
Pleural Effusion      R only    None     None       None         Bilateral
Ascites               None      None     None       None         Present
Pericardial Eff.      None      None     None       None         Present

Total Active Lesions:  ~8        ~6        ~5         ~5          ~18

================================================================================
END OF TRAJECTORY ANALYSIS
================================================================================
